Viewing Study NCT04517292

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:49 PM
Ignite Modification Date: 2026-02-03 @ 9:16 PM
Study NCT ID: NCT04517292
Status: UNKNOWN
Last Update Posted: 2020-08-18
First Post: 2020-08-16
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)
Sponsor: Fudan University
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None triple negative breast cancer View
None first line chemotherapy View
None Eribulin View
None Cisplatin View